{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone&page=2", "query": { "intervention": "Placebo to risperidone", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 58, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T17:54:49.035Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01556763", "title": "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Central Nervous System Diseases" ], "interventions": [ { "name": "EVP-6124 (0.3 mg/day)", "type": "DRUG" }, { "name": "EVP-6124 (1.0 mg/day)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antipsychotic therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "FORUM Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 21, "start_date": "2008-04", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-06-21", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 1, "location_summary": "Wichita, Kansas", "locations": [ { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01556763" }, { "nct_id": "NCT04512066", "title": "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia, Schizoaffective Disorder" ], "interventions": [ { "name": "RO6889450", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 287, "start_date": "2020-09-08", "completion_date": "2022-06-21", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04512066" }, { "nct_id": "NCT01171937", "title": "Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "8 Years to 16 Years" }, "enrollment_count": 41, "start_date": "2008-09", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01171937" }, { "nct_id": "NCT00509067", "title": "Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Galantamine", "type": "DRUG" }, { "name": "CDP-choline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2007-11", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-04-11", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509067" }, { "nct_id": "NCT02109562", "title": "Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "RBP-7000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indivior Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 354, "start_date": "2014-04", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 32, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109562" }, { "nct_id": "NCT00921804", "title": "Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "AZD 8529", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo to match AZD8529", "type": "DRUG" }, { "name": "Placebo to match risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 296, "start_date": "2009-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2010-06-30", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 3, "location_summary": "Garden Grove, California • Glendale, California • Rockville, Maryland", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00921804" }, { "nct_id": "NCT00140426", "title": "A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anorexia Nervosa" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "21 Years", "sex": "FEMALE", "summary": "12 Years to 21 Years · Female only" }, "enrollment_count": 41, "start_date": "2004-08", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2016-02-02", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00140426" }, { "nct_id": "NCT01272752", "title": "Anti-psychotic Medication (New Use) Weight Loss Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "IHBG-10", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Avera McKennan Hospital & University Health Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-04", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2012-06-01", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01272752" }, { "nct_id": "NCT00132678", "title": "A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Risperdal Consta", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 559, "start_date": "2005-02", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2013-07-29", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • La Mesa, California • National City, California + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00132678" }, { "nct_id": "NCT07565428", "title": "Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Negative Symptoms of Schizophrenia" ], "interventions": [ { "name": "Roluperidone", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "aripiprazole", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Minerva Neurosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 380, "start_date": "2026-04-23", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-05T17:54:49.035Z", "location_count": 13, "location_summary": "Bellflower, California • Culver City, California • Garden Grove, California + 10 more", "locations": [ { "city": "Bellflower", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Hallandale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07565428" } ] }